Amgen Reports Positive Late-Stage Trial Results for Experimental Drug Targeting Sjögren’s Disease
Amgen reported positive topline results from a late-stage trial of dazodalibep, an experimental therapy targeting Sjögren's disease. The Phase 3 OASIZ study met its primary endpoint, leading the company to trade higher in premarket trading on Tuesday. Sjögren’s is an autoimmune disorder with limited treatment options, and a successful outcome for Amgen could position dazodalibep as a potential new therapy option. This development marks progress toward regulatory submission if further trials confirm these results.
Tickers: $AMGN
Topics: Amgen autoimmune_disease pharmaceuticals